Cargando…

Treatment of diabetic kidney disease: current and future targets

Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease in Korea and worldwide, and is a risk factor for the development of cardiovascular complications. The conventional treatments for DKD are control of blood glucose and blood pressure levels by inhibiting the renin-angiotensin...

Descripción completa

Detalles Bibliográficos
Autor principal: Kim, Mi-Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511942/
https://www.ncbi.nlm.nih.gov/pubmed/28704915
http://dx.doi.org/10.3904/kjim.2016.219
_version_ 1783250422962585600
author Kim, Mi-Kyung
author_facet Kim, Mi-Kyung
author_sort Kim, Mi-Kyung
collection PubMed
description Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease in Korea and worldwide, and is a risk factor for the development of cardiovascular complications. The conventional treatments for DKD are control of blood glucose and blood pressure levels by inhibiting the renin-angiotensin system. However, the prevalence of DKD continues to increase and additional therapies are required to prevent or ameliorate the condition. Many drugs have been, or are being, developed to target the molecular mechanisms in play in DKD. This review focuses on DVD treatment, considering current and emerging therapeutic targets and the clinical trial-based evidence.
format Online
Article
Text
id pubmed-5511942
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Korean Association of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-55119422017-07-17 Treatment of diabetic kidney disease: current and future targets Kim, Mi-Kyung Korean J Intern Med Review Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease in Korea and worldwide, and is a risk factor for the development of cardiovascular complications. The conventional treatments for DKD are control of blood glucose and blood pressure levels by inhibiting the renin-angiotensin system. However, the prevalence of DKD continues to increase and additional therapies are required to prevent or ameliorate the condition. Many drugs have been, or are being, developed to target the molecular mechanisms in play in DKD. This review focuses on DVD treatment, considering current and emerging therapeutic targets and the clinical trial-based evidence. The Korean Association of Internal Medicine 2017-07 2017-06-30 /pmc/articles/PMC5511942/ /pubmed/28704915 http://dx.doi.org/10.3904/kjim.2016.219 Text en Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Kim, Mi-Kyung
Treatment of diabetic kidney disease: current and future targets
title Treatment of diabetic kidney disease: current and future targets
title_full Treatment of diabetic kidney disease: current and future targets
title_fullStr Treatment of diabetic kidney disease: current and future targets
title_full_unstemmed Treatment of diabetic kidney disease: current and future targets
title_short Treatment of diabetic kidney disease: current and future targets
title_sort treatment of diabetic kidney disease: current and future targets
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511942/
https://www.ncbi.nlm.nih.gov/pubmed/28704915
http://dx.doi.org/10.3904/kjim.2016.219
work_keys_str_mv AT kimmikyung treatmentofdiabetickidneydiseasecurrentandfuturetargets